These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 6179448)

  • 1. Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen.
    Laurence J; Coleman M; Allen SL; Silver RT; Pasmantier M
    Ann Intern Med; 1982 Aug; 97(2):190-5. PubMed ID: 6179448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [COP-BLAM III regimen for elderly non-Hodgkin's lymphoma].
    Niitsu N; Umeda M; Shirai T
    Nihon Ronen Igakkai Zasshi; 1993 Sep; 30(9):753-8. PubMed ID: 7693992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma.
    Coleman M; Armitage JO; Gaynor M; McDermott D; Weisenburger DD; Adler K; Beshevkin M; Silver RT; Reisman AM; Pasmantier MW
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):23-33. PubMed ID: 2456620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.
    Schein PS; DeVita VT; Hubbard S; Chabner BA; Canellos GP; Berard C; Young RC
    Ann Intern Med; 1976 Oct; 85(4):417-22. PubMed ID: 61732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of CHOP and COP-BLAM chemotherapy in highly malignant non-Hodgkin's lymphoma].
    Gerhartz HH; Thiel E; Hiller E; Nerl C; Wilmanns W; Huhn D
    Dtsch Med Wochenschr; 1986 Oct; 111(40):1511-5. PubMed ID: 2428572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in chemotherapy for large cell lymphoma.
    Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU), cyclophosphamide, vincristine- and prednisone-(BCOP). A new therapeutic regimen for diffuse histiocytic lymphoma.
    Durant JR; Loeb V; Dorfman R; Chan YK
    Cancer; 1975 Dec; 36(6):1936-44. PubMed ID: 1106833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma.
    Niitsu N; Umeda M
    Eur J Haematol; 1996 Mar; 56(3):163-7. PubMed ID: 8598236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential cyclophosphamide-prednisone and vincristine-bleomycin (CPOB). An effective, schedule-dependent treatment for advanced diffuse histiocytic lymphoma.
    Johnson GJ; Costello WG; Oken MM; Sponzo RW; Barnes JM; Ezdinli EZ; Bennett JM; Silverstein MN; Glick JH; Berard CW
    Cancer; 1983 Oct; 52(7):1133-41. PubMed ID: 6192894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COP-BLAM regimen combined with granulocyte colony-stimulating factor and high-grade non-Hodgkin's lymphoma.
    Niitsu N; Umeda M
    Eur J Haematol; 1995 Aug; 55(2):88-92. PubMed ID: 7543059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COP-BLAM multidrug infusion chemotherapies for lymphoma: results in a community hospital setting.
    Topilow AA; Guerra OR; Tarantolo SR; Lerner WA; Snyder GC
    Cancer Invest; 1993; 11(4):371-8. PubMed ID: 7686808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma.
    Newcomer LN; Cadman EC; Nerenberg MI; Chen M; Bertino JR; Farber LR; Prosnitz LR
    Cancer Treat Rep; 1982 Jun; 66(6):1279-84. PubMed ID: 6177407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response and adverse drug reactions to combination chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma: comparison of CHOP, COP-BLAM, COP-BLAM III, and THP-COPBLM.
    Niitsu N; Umeda M
    Eur J Haematol; 1999 Nov; 63(5):337-44. PubMed ID: 10580566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [COP-BLAM therapy for a Hodgkin's disease in the elderly].
    Niitsu N; Nakayama M; Umeda M
    Nihon Ronen Igakkai Zasshi; 1999 Jun; 36(6):412-5. PubMed ID: 10513213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A comparative study of CHOP therapy and COP-BLAM therapy for non-Hodgkin's lymphoma in elderly patients].
    Arai N; Hara A; Kaneko H; Umeda M; Shirai T
    Nihon Ronen Igakkai Zasshi; 1991 Sep; 28(5):672-7. PubMed ID: 1721658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy.
    Fisher RI; DeVita VT; Johnson BL; Simon R; Young RC
    Am J Med; 1977 Aug; 63(2):177-82. PubMed ID: 70170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
    Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A
    N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The COP-BLAM therapy for malignant lymphoma].
    Arai N; Hara A; Umeda M; Shirai T
    Rinsho Ketsueki; 1990 Jul; 31(7):951-7. PubMed ID: 1699008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
    Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.